Management of PRN Blood Pressure in Intracranial Hemorrhage

Target Blood Pressure Goals

The European Society of Cardiology recommends that for patients with spontaneous intracranial hemorrhage, blood pressure should be lowered to a target systolic BP of 140-160 mmHg, initiated within 2 hours of onset and reaching target within 1 hour 1, 2
Acute lowering of systolic BP to <130 mmHg is potentially harmful and should be avoided as it may compromise cerebral perfusion 1, 2
For patients presenting with SBP >150 mmHg and <220 mmHg, acute lowering of SBP to 140 mmHg is safe and may improve functional outcomes 2
For patients with very high BP (>220 mmHg), more cautious BP lowering may be required due to higher rates of neurological deterioration and renal adverse events 2

The American Heart Association recommends labetalol as the first-line agent for PRN blood pressure control in ICH, with dosing of 5-20 mg IV bolus every 15 minutes or continuous infusion at 2 mg/min 3, 2
Labetalol leaves cerebral blood flow relatively intact and does not increase intracranial pressure 3

The American Stroke Association suggests that nicardipine is an alternative first-line agent, particularly favored in North America, with dosing starting at 5 mg/hour IV infusion 4, 5
Urapidil (α-adrenoreceptor blocker) is commonly used in some regions, particularly in China, for blood pressure management in ICH patients 4, 5

The European Society of Cardiology recommends maintaining cerebral perfusion pressure (CPP) >60 mmHg to prevent cerebral hypoperfusion 6, 2
The American Heart Association advises avoiding venous vasodilators like nitroprusside as they may have negative effects on hemostasis and intracranial pressure 3, 2
Excessive acute drops in systolic BP (>70 mmHg) may be associated with acute renal injury and early neurological deterioration 1
For patients with evidence of elevated intracranial pressure (ICP), the Neurocritical Care Society recommends considering ICP monitoring and maintaining cerebral perfusion pressure at 60-80 mmHg 2

The American Heart Association recommends that patients with intracranial hemorrhage should have their systolic blood pressure controlled with intravenous agents to prevent hematoma expansion, as oral regimens may be insufficient in the acute setting 7, 8

Continuous arterial line monitoring is essential for patients requiring continuous IV antihypertensives, as automated cuff monitoring is inadequate, allowing for precise titration to avoid excessive BP drops 9
The European Society of Cardiology suggests avoiding precipitous BP drops, as never dropping systolic BP by more than 70 mmHg acutely is associated with acute renal injury and early neurological deterioration 8
Gradual reduction of blood pressure over hours is safer than rapid correction, according to the International Journal of Stroke 10

Admission to a neuroscience intensive care unit may reduce mortality, and frequent neurological assessments using standardized scales, such as the NIHSS and Glasgow Coma Scale, are recommended 9
Monitoring for signs of neurological deterioration that might indicate hematoma expansion or cerebral hypoperfusion is crucial, and consideration of ICP monitoring may be necessary if there is evidence of elevated intracranial pressure 9

The European Heart Journal recommends transitioning back to oral agents with appropriate dose adjustments once acute BP control is achieved with IV agents and the patient is stable, typically after 24-48 hours 8

In patients with acute intracerebral hemorrhage presenting with a systolic blood pressure of 150–220 mmHg, the guideline recommends lowering SBP to 140 mmHg (acceptable range 130–150 mmHg) and achieving this target within the first hour of treatment initiation. This recommendation is based on evidence from a 2010 Stroke study 11.

Admission of patients with acute intracerebral hemorrhage to a neuroscience intensive‑care unit is linked to a reduction in in‑hospital mortality compared with non‑specialized wards, as reported in the same 2010 Stroke cohort 11.